News Releases

Date Title and Summary Additional Formats
Toggle Summary Cidara Completes $32M Series A Financing
Veteran team to apply novel, small molecule immunotherapy platform to treat severe fungal infections in immune compromised patients. Cidara has completed a $32 million Series A financing that will enable it to advance candidates from the company’s Cloudbreak™ targeted immunotherapy platform and
View HTML
Toggle Summary Cidara Therapeutics to Present Data from Antifungal Drug Development Program at ICAAC
Results from nonclinical studies of Cidara’s lead candidate CD101 IV (formerly biafungin), a novel, long-acting echinocandin, will be presented this week at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Washington D.C.
View HTML
Toggle Summary Cidara Named to FierceBiotech’s Fierce 15
Cidara has been named by FierceBiotech as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. “Welcome back Jeff Stein and Kevin Judice, two biotech execs who are part of the new biotech redux generation,”
View HTML
Toggle Summary Cidara Appoints Paul Daruwala to Chief Commercial Officer and James Balkovec to SVP of Research
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today the appointments of Paul Daruwala as chief commercial officer and James Balkovec, Ph.D. as senior vice president, Research.
View HTML
Toggle Summary Cidara Completes $42 Million Private Series B Financing
Proceeds Will Advance Novel Anti-Infectives into Clinical Studies Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today the completion of a $42 million private Series B financing.
View HTML
Toggle Summary Robert Perez and Timothy Franson Join Cidara Board of Directors
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today that Robert J. Perez and Timothy R. Franson, M.D., have joined the company’s Board of Directors. “Mr. Perez and Dr.
View HTML
Toggle Summary Cidara Therapeutics Announces Pricing of Initial Public Offering
SAN DIEGO , April 15, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced the pricing of its initial public offering of 4,800,000 shares of common stock,
View HTML
Toggle Summary FDA Grants QIDP and Fast Track Designations to CD101 IV, Cidara Therapeutics’ Lead Antifungal Product Candidate
-CD101 IV designated for treatment of serious or life-threatening Candida infections- SAN DIEGO --(BUSINESS WIRE)--May 11, 2015-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today
View HTML
Toggle Summary Cidara Reports First Quarter 2015 Financial Results and Provides Corporate Update
SAN DIEGO , May 21, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the quarter ended March 31, 2015 and provided an update on
View HTML
Toggle Summary Cidara Therapeutics Set to Join Russell Indexes
SAN DIEGO , June 23, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that it is set to join the Russell 3000 ® , Russell 2000 ® , and Russell Microcap
View HTML
Toggle Summary Cidara Therapeutics Initiates Phase 1 Study of Lead Antifungal Product Candidate CD101 IV
SAN DIEGO --(BUSINESS WIRE)--Aug. 3, 2015-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced the initiation of a Phase 1, randomized, double-blind, dose-escalation study to
View HTML
Toggle Summary Cidara Therapeutics to Present at the Wedbush PacGrow 2015 Healthcare Conference
SAN DIEGO , Aug. 5, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Wedbush PacGrow 2015 Healthcare Conference.
View HTML
Toggle Summary Cidara Therapeutics to Present Data from Antifungal Drug Development Programs at ICAAC/ICC 2015 Meeting
- Sixteen abstracts summarize evaluations of company's novel echinocandin CD101 and Cloudbreak ™ immunotherapy platform - SAN DIEGO --(BUSINESS WIRE)--Aug. 10, 2015-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat
View HTML
Toggle Summary Cidara Reports Second Quarter 2015 Financial Results and Provides Corporate Update
SAN DIEGO , Aug. 11, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three and six months ended June 30, 2015 and provided an
View HTML
Toggle Summary Cidara Therapeutics Presents Results from Key Studies Evaluating Its Novel Echinocandin CD101 at ICAAC/ICC 2015
– New Data Support CD101’s Potential as a Potent Treatment for Serious Fungal Infections and Highlight Progress in Company’s Robust Antifungal Drug-Development Program – SAN DIEGO --(BUSINESS WIRE)--Sep. 19, 2015-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel
View HTML
Toggle Summary Cidara Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference in London
SAN DIEGO , Nov. 10, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Jefferies 2015 Global Healthcare Conference in
View HTML
Toggle Summary Cidara Therapeutics Announces Positive Data From Phase 1 Clinical Trial of CD101 IV and Reports Third Quarter 2015 Financial Results
-- Single Ascending Dose Study-Results Demonstrate Excellent Safety and Tolerability and Support Once-Weekly IV Dosing -- -- Management to Host Webcast and Conference Call Tomorrow at 8:00 a.m. ET -- SAN DIEGO , Nov. 16, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc.
View HTML
Toggle Summary Cidara Therapeutics Commends IDSA for New Candidiasis Clinical Management Guidelines
New Guidelines Recommend Echinocandins as First-Line Treatment for Deadly Fungal Infections in High-Risk Patients SAN DIEGO --(BUSINESS WIRE)--Dec. 21, 2015-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and
View HTML
Toggle Summary Cidara Therapeutics Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CD101 IV
-- Multiple Ascending Dose Study-Results Reinforce Excellent Safety and Tolerability – SAN DIEGO --(BUSINESS WIRE)--Jan. 11, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today
View HTML
Toggle Summary Cidara Therapeutics Announces Participation in Leerink Partners 5th Annual Global Healthcare Conference
SAN DIEGO , Feb. 03, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Leerink Partners 5 th Annual Global Healthcare
View HTML
Toggle Summary Cidara Receives Orphan Drug Designation for Novel Echinocandin, CD101 IV, in Candidemia and Invasive Candidiasis
Orphan designation follows QIDP and Fast Track status for CD101 IV SAN DIEGO --(BUSINESS WIRE)--Feb. 10, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the U.S.
View HTML
Toggle Summary Cidara Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
SAN DIEGO , March 18, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three months and full year ended December 31, 2015 and
View HTML
Toggle Summary Cidara Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference
SAN DIEGO , April 05, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Needham & Company 15 th Annual Healthcare
View HTML
Toggle Summary Cidara Therapeutics Announces Presentation of Data from its Antifungal Drug Development Programs at ECCMID 2016
Presentations to Highlight Results from the Phase 1 Study of Novel Echinocandin CD101 IV Demonstrating Excellent Safety and Supporting Once-Weekly Dosing SAN DIEGO --(BUSINESS WIRE)--Apr. 6, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives
View HTML
Toggle Summary Cidara Reports First Quarter 2016 Financial Results and Provides Corporate Update
SAN DIEGO , May 12, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three months ended March 31, 2016 and provided an update
View HTML
Toggle Summary FDA Grants QIDP and Fast Track Designation to CD101 Topical, Cidara Therapeutics’ Novel Antifungal Product Candidate
-CD101 Topical designated for treatment of VVC and for prevention of recurrent VVC- SAN DIEGO --(BUSINESS WIRE)--May 31, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced
View HTML
Toggle Summary Cidara Therapeutics to Present at the Jefferies 2016 Healthcare Conference
SAN DIEGO , June 02, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Jefferies 2016 Healthcare Conference
View HTML
Toggle Summary Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016
Results from Multiple Dose Phase 1 Trial of CD101 IV Supporting High-Exposure, Once-Weekly Dosing Will Be Presented For the First Time SAN DIEGO --(BUSINESS WIRE)--Jun. 8, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to
View HTML
Toggle Summary Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis
SAN DIEGO --(BUSINESS WIRE)--Jun. 9, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the first patient has been dosed in RADIANT, a Phase 2 clinical trial
View HTML
Toggle Summary Cidara Therapeutics Expands Management Team
SAN DIEGO , July 05, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced the addition of Neil Abdollahian and Matt Onaitis to the executive management
View HTML
Toggle Summary Cidara Therapeutics to Present at the Cantor Fitzgerald Annual Healthcare Conference
SAN DIEGO , July 06, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the 2 nd Annual Cantor Fitzgerald Healthcare
View HTML
Toggle Summary Cidara Therapeutics Announces Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting
Presentations Will Highlight Data from Studies of Novel Echinocandin CD101 and Reinforce the Unmet Need for Effective New VVC Treatments SAN DIEGO --(BUSINESS WIRE)--Aug. 9, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies
View HTML
Toggle Summary Cidara Reports Second Quarter 2016 Financial Results and Provides Corporate Update
SAN DIEGO , Aug. 11, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three months ended June 30, 2016 and provided an update
View HTML
Toggle Summary Cidara Therapeutics Announces Clinical Management Team Changes
SAN DIEGO --(BUSINESS WIRE)--Sep. 1, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced that the company has named Taylor Sandison , M.D., M.P.H., its vice president, clinical
View HTML
Toggle Summary Cidara Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
SAN DIEGO , Sept. 20, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will participate in a fireside chat at the Leerink Partners Roundtable
View HTML
Toggle Summary Cidara Therapeutics Selects First Development Candidate from its CloudbreakTM Immunotherapy Discovery Platform
CD201 Demonstrates Potential to Treat Life-Threatening Multi-Drug Resistant Gram-negative Bacterial Infections SAN DIEGO --(BUSINESS WIRE)--Sep. 21, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced
View HTML
Toggle Summary Cidara Therapeutics Announces Commencement of Public Offering of Common Stock
SAN DIEGO , Oct. 06, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has commenced an underwritten public offering of its common stock.
View HTML
Toggle Summary Cidara Therapeutics Announces Pricing of Public Offering of Common Stock
SAN DIEGO , Oct. 07, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing of an underwritten public offering of 2,475,248 shares of its common stock at a price to the public
View HTML
Toggle Summary Cidara Therapeutics Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriter’s Option to Purchase Additional Shares
SAN DIEGO , Oct. 13, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the closing of its previously announced underwritten public offering of 2,475,248 shares of its common stock,
View HTML
Toggle Summary Cidara Therapeutics Announces Data from Studies of Novel Antifungal CD101 to be Presented at ACCP and IDWeek Annual Meetings
Data Highlight Safety and Efficacy of CD101 IV and CD101 Topical for the Treatment of Fungal Infections SAN DIEGO --(BUSINESS WIRE)--Oct. 24, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that
View HTML
Toggle Summary Cidara Therapeutics and Square 1 Bank Announce $20 Million Credit Facility
SAN DIEGO , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, and Square 1 Bank, a division of Pacific Western Bank , announced they have entered into an
View HTML
Toggle Summary Cidara Therapeutics to Present at the Stifel 2016 Healthcare Conference
SAN DIEGO , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced it will participate in the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 .
View HTML
Toggle Summary Cidara Therapeutics to Present Data on Novel Antifungal CD101 at the Global Joint Conference of ICHS and INFOCUS
Data Will Highlight the Potential Broad Clinical Utility and Subcutaneous Administration of CD101 for Invasive Fungal Infections SAN DIEGO --(BUSINESS WIRE)--Nov. 10, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies,
View HTML
Toggle Summary Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results
SAN DIEGO , Nov. 10, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2016 and provided an update on its corporate
View HTML
Toggle Summary Cidara Therapeutics’ Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies
SAN DIEGO --(BUSINESS WIRE)--Nov. 28, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 will be
View HTML
Toggle Summary Newly Published Data Reinforce Growing Body of Evidence Supporting Cidara Therapeutics’ Lead Antifungal CD101
Data Showcase Compound’s Discovery through Development and Potential to Expand Echinocandin Utility Across Multiple Infectious-Disease Indications SAN DIEGO --(BUSINESS WIRE)--Dec. 14, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including
View HTML
Toggle Summary Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis
Topline Data Expected in First Quarter 2017 SAN DIEGO --(BUSINESS WIRE)--Jan. 4, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the completion of patient enrollment in the RADIANT trial, a Phase 2
View HTML
Toggle Summary Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC
Further Development of CD101 Topical for VVC to be discontinued CD101 IV development program in candidemia and invasive candidiasis (including Phase 2 STRIVE trial) continuing and remains on track Company to Host Conference Call Today at 5:30 a.m. PT SAN DIEGO , Feb.
View HTML
Toggle Summary Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
SAN DIEGO , March 15, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2016 and provided an update on its
View HTML
Toggle Summary Cidara Therapeutics to Host Investor Day on April 6, 2017
SAN DIEGO , March 29, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, will host an Investor Day on Thursday, April 6, 2017 , from 8:30 a.m. to 11:30 a.m. EDT ( 5:30 a.m. to 8:30 a.m.
View HTML
Toggle Summary Cidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance Development of its First CloudbreakTM Antibiotic Immunotherapy
CARB-X Funding to Advance Novel First-in-Class Bispecific Immunotherapy to Fight Multi-drug Resistant Bacterial Infections SAN DIEGO --(BUSINESS WIRE)--Mar. 30, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today
View HTML
Toggle Summary Cidara Therapeutics to Present Data on Novel Antifungal CD101 and Cloudbreak Antibacterial Immunotherapy at ECCMID and SID Annual Meetings
SAN DIEGO --(BUSINESS WIRE)--Apr. 17, 2017-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from nonclinical studies of its novel echinocandin antifungal CD101 and its Cloudbreak TM antibacterial
View HTML
Toggle Summary Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer
SAN DIEGO --(BUSINESS WIRE)--Apr. 25, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Taylor Sandison , M.D., M.P.H., has been named chief medical officer (CMO) of the company. Dr.
View HTML
Toggle Summary Cidara Provides Corporate Update and Reports First Quarter 2017 Financial Results
SAN DIEGO , May 10, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2017 and provided an update on its corporate activities and
View HTML
Toggle Summary Cidara Therapeutics Announces Presentations at ASM Microbe 2017 and the 22nd Congress of the European Hematology Association
Data Highlight Expanded Utility of CD101 for Potential Treatment and Prevention of Serious Fungal Infections SAN DIEGO --(BUSINESS WIRE)--May 30, 2017-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that
View HTML
Toggle Summary Cidara Therapeutics to Participate in the 2017 BIO International Convention
Panel Discussion Will Highlight Urgent Needs and Opportunities in Antifungal Development SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein ,
View HTML
Toggle Summary Cidara Therapeutics to Participate in Anti-Infectives Panel Discussion at the 2017 Infectious Diseases Summit
SAN DIEGO --(BUSINESS WIRE)--Jul. 6, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer, will be participating in a panel discussion at
View HTML
Toggle Summary Cidara Therapeutics Announces Publication of Results from In Vivo Study Investigating Novel Antifungal CD101 in Intra-Abdominal Candidiasis (IAC)
Data published in Antimicrobial Agents and Chemotherapy demonstrate CD101 has superior tissue and lesion penetration compared to the current standard of care SAN DIEGO --(BUSINESS WIRE)--Aug. 1, 2017-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives
View HTML
Toggle Summary Cidara Provides Corporate Update and Reports Second Quarter 2017 Financial Results
SAN DIEGO , Aug. 09, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended June 30, 2017 and provided an update on its corporate activities and
View HTML
Toggle Summary T2 Biosystems and Cidara Therapeutics Announce Partnership for Commercial Placement of T2Dx Instruments to Support CD101 Drug Trials
Exclusive pricing program designed to drive uptake of T2 Biosystems' products and accelerate enrollment in Cidara's CD101 trials, targeting deadly sepsis-causing pathogen Candida LEXINGTON, Mass. and SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc.
View HTML
Toggle Summary Cidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance Congress
SAN DIEGO , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., the company’s president and chief executive officer, will participate in a keynote
View HTML
Toggle Summary Cidara Therapeutics to Present at Two Upcoming Conferences
SAN DIEGO , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer of Cidara, is scheduled to present at two
View HTML
Toggle Summary Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology Meeting
Data Highlight Advantages of CD101 in Difficult-to-Treat Infections SAN DIEGO , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies
View HTML
Toggle Summary Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock
SAN DIEGO , Oct. 19, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing of a private placement of 3,360,000 shares of its common stock at a price of $6.00 per share.
View HTML
Toggle Summary Cidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate Update
SAN DIEGO , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will report third quarter 2017 financial results after the close of U.S.
View HTML
Toggle Summary Cidara Provides Corporate Update and Reports Third Quarter 2017 Financial Results
Conference call and webcast today at 1:05 p.m. PST/4:05 p.m. EST SAN DIEGO , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended
View HTML
Toggle Summary Cidara Therapeutics Named a San Diego Metro Area 2017 Top Workplace
Employee feedback places company among top 10 in San Diego Metro Area SAN DIEGO , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a 2017 Top
View HTML
Toggle Summary Cidara Therapeutics Completes Enrollment in Phase 2 STRIVE Trial Evaluating Novel Antifungal Rezafungin (CD101 IV) in Invasive Fungal Infections
Topline Data Expected in First Quarter 2018 SAN DIEGO , Nov. 28, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the completion of patient enrollment in the STRIVE trial, a Phase 2
View HTML
Toggle Summary Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections
Authors Highlight How New Options Can be Used to Augment Antifungal Treatment and Prophylaxis Strategies SAN DIEGO , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that a
View HTML
Toggle Summary Cidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem Meeting
Data Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections in Immunocompromised Patients SAN DIEGO , Jan. 29, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including
View HTML
Toggle Summary Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2017 , and provided an update on its
View HTML
Toggle Summary Cidara Announces Appointment of Chrysa Mineo as Independent Director
SAN DIEGO , March 01, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointment of Chrysa Mineo to the company’s board of directors. Ms.
View HTML
Toggle Summary Cidara Therapeutics to Present Rezafungin Data at the European Society for Blood and Marrow Transplantation 2018 Meeting
SAN DIEGO , March 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that two rezafungin abstracts have been accepted for presentation at the 44 th Annual Meeting of the European
View HTML
Toggle Summary Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin
Favorable safety, tolerability, and efficacy observed in novel once-weekly echinocandin for difficult-to-treat invasive fungal infections Phase 3 studies for both treatment and prevention on track to start mid-2018 Company to host conference call today at 8:00 a.m. ET / 5:00 a.m.
View HTML
Toggle Summary Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin
Additional data and analyses from  STRIVE Phase 2 clinical trial confirm positive efficacy results in both rezafungin arms Definitive Phase 1 QT clinical trial showed no cardiac abnormalities SAN DIEGO , March 21, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc.
View HTML
Toggle Summary Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting
Company secures four oral presentations, including three that will highlight new data demonstrating activity of rezafungin against Candida auris and azole-resistant Aspergillus SAN DIEGO --(BUSINESS WIRE)--Apr. 4, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing
View HTML
Toggle Summary Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results
SAN DIEGO , May 10, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2018 and provided an update on its corporate activities and
View HTML
Toggle Summary Cidara Therapeutics Announces Offering of Common Stock and Warrants
SAN DIEGO , May 21, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has entered into a securities purchase agreement with certain investors providing for the purchase and
View HTML
Toggle Summary Cidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH to Support Development of Novel Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial Infections
New Partnership to Jointly Conduct Preclinical Development of Cidara’s Cloudbreak Antibody-Drug Conjugates SAN DIEGO --(BUSINESS WIRE)--May 21, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that
View HTML
Toggle Summary Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara’s Rezafungin for the Treatment of Invasive Fungal Infections
Four accepted presentations include a late-breaker featuring Phase 2 STRIVE trial data and three posters describing the activity of rezafungin against fungal pathogens SAN DIEGO --(BUSINESS WIRE)--May 23, 2018-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel
View HTML
Toggle Summary Cidara Therapeutics Announces Oral Presentations on Rezafungin at Two Upcoming Global Conferences
Data Will Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today
View HTML
Toggle Summary Cidara Provides Corporate Update and Reports Second Quarter 2018 Financial Results
SAN DIEGO , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended June 30, 2018 and provided an update on its corporate activities
View HTML
Toggle Summary Cidara Therapeutics to Present New Cloudbreak Data at the ESCMID/ASM Conference and 16th Annual Discovery on Target Meeting
Data highlight potential of Cloudbreak immunotherapy candidates for the treatment of multi-drug resistant Gram-negative bacterial infections SAN DIEGO --(BUSINESS WIRE)--Sep. 4, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including
View HTML
Toggle Summary Cidara Therapeutics to Present Data on Lead Antifungal Rezafungin at IDWeek 2018
Presentations will highlight data demonstrating the broad clinical utility, safety and potency of rezafungin to fight invasive fungal infections SAN DIEGO --(BUSINESS WIRE)--Sep. 12, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including
View HTML
Toggle Summary Cidara Therapeutics Appoints David Gollaher, Ph.D., to Board of Directors
Former Head of Global Government Affairs and Policy at Gilead Sciences led wide-ranging collaborations with leading academic institutions and non-profit groups SAN DIEGO --(BUSINESS WIRE)--Sep. 12, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel
View HTML
Toggle Summary Cidara Therapeutics to Present at Two Upcoming Investor Conferences
SAN DIEGO , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer of Cidara, is scheduled to present at two
View HTML
Toggle Summary FDA Grants QIDP and Fast Track Designations to Cidara Therapeutics’ Rezafungin Prophylaxis Development Program
Rezafungin designated for the prevention of invasive fungal infections in adults undergoing bone marrow transplantation SAN DIEGO --(BUSINESS WIRE)--Sep. 25, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today
View HTML
Toggle Summary Cidara Therapeutics Initiates Phase 3 Trial of Lead Antifungal Rezafungin for Treatment of Invasive Candida Infections
SAN DIEGO --(BUSINESS WIRE)--Sep. 27, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and
View HTML
Toggle Summary Cidara Therapeutics Presents Results from Successful Phase 2 STRIVE Trial Evaluating Rezafungin at IDWeek 2018
STRIVE clinical trial successfully met all primary endpoints demonstrating the efficacy and safety of rezafungin for the treatment of invasive fungal infections Rezafungin data featured in one oral and three poster presentations showcase broad clinical utility of Cidara’s novel once-weekly
View HTML
Toggle Summary Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference
SAN DIEGO --(BUSINESS WIRE)--Oct. 15, 2018-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in
View HTML